Brain Tumor Diagnosis and Treatment - Global Market Trajectory & Analytics

Global Brain Tumor Diagnosis and Treatment Market to Reach $887.5 Million by 2027

Amid the COVID-19 crisis, the global market for Brain Tumor Diagnosis and Treatment estimated at US$537.5 Million in the year 2020, is projected to reach a revised size of US$887.5 Million by 2027, growing at a CAGR of 7.4% over the period 2020-2027. Primary Brain Tumor, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$587.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Secondary Brain Tumor segment is readjusted to a revised 7.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR

The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$197 Million by the year 2027 trailing a CAGR of 11.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 6.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Select Competitors (Total 42 Featured):

• AstraZeneca PLC
• Carestream Health, Inc.
• GE Healthcare
• Hitachi Medical Corporation
• Merck & Co., Inc.
• Pfizer, Inc.
• Philips Healthcare
• Shimadzu Corporation
• Siemens Healthineers
• Toshiba Medical Systems Corporation